The legal action, spearheaded by the Rosen Law Firm, centers on claims that Insulet failed to disclose critical defects in its production procedures. According to the complaint, these procedural failures created foreseeable risks that company products would violate safety regulations or jeopardize patient health. Plaintiffs argue that these undisclosed risks rendered the company's public statements throughout the designated class period materially false and misleading, ultimately resulting in investor financial losses when the information became public.

While the lawsuit has been filed, no class has yet been certified by the court. Investors are not currently represented by counsel unless they choose to retain a firm. Participation in a potential future recovery does not mandate serving as a lead plaintiff, and shareholders maintain the right to remain absent members or select their own legal representation. Those interested in joining the action or seeking lead status can contact Phillip Kim at the Rosen Law Firm via their website or by calling 866-767-3653.